参芪颗粒配合低剂量化疗肝动脉介入栓塞治疗中晚期肝癌的临床研究  

Clinical study of Shenqi granule combined with low-dose chemotherapy for hepatic artery interventional embolization in the treatment of advanced liver cancer

作　　者：刘治辉 LIU Zhihui(Department of Oncology,Xuchang Municipal Hospital,Xuchang 461000,China)

机构地区：[1]许昌市立医院肿瘤科,许昌461000

出　　处：《上海医药》2022年第3期42-45,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探究参芪颗粒配合低剂量化疗肝动脉介入栓塞(TACE)治疗中晚期肝癌的临床疗效。方法:选取60例中晚期肝癌患者,用随机数字表法分为观察组(n=30)和对照组(n=30)。对照组给予常规剂量TACE治疗,观察组给予参芪颗粒配合低剂量化疗TACE治疗。比较两组的临床疗效和安全性。结果:治疗后,观察组的疾病控制率、中医症状改善率、甲胎蛋白有效率、白细胞计数水平等高于对照组(P<0.05),各不良反应发生率低于对照组(P<0.05)。结论:参芪颗粒配合低剂量化疗TACE治疗中晚期肝癌可改善肝功能,提高临床疗效,降低不良反应。Objective:To investigate the clinical efficacy of Shenqi granule combined with low-dose chemotherapy for hepatic transcatheter artery interventional chemoembolization(TACE)in the treatment of advanced hepatocellular carcinoma.Methods:Sixty patients with advanced liver cancer were selected and randomly divided into an observation group(n=30)and a control group(n=30).The control group was treated with conventional doses of TACE while the observation group with Shenqi granules combined with low-dose chemotherapy TACE.The clinical efficacy and safety were compared between the two groups.Results:After the treatment,the disease control rate,the traditional Chinese medicine symptom improvement rate,α-fetoprotein effective rate,and white blood cell counting level were higher and the incidence of adverse reactions was lower in the observation group than the control group(P<0.05).Conclusion:Shenqi granules combined with low-dose chemotherapy TACE for the treatment of advanced liver cancer can improve liver function and clinical efficacy and reduce the incidence of adverse reactions.

关 键 词：肝癌 中晚期 化疗 肝动脉介入栓塞 参芪颗粒 

分 类 号：R286[医药卫生—中药学] R735.7[医药卫生—中医学]